Conversely, in tumour samples with low NLRP1 expression, there is a notable enrichment of signalling pathways, include E2F targets, G2/M checkpoint, MYC targets version 1, MYC targets version 2 and oxidative phosphorylation (Figure 10). The gene discussed is NLRP1; the disease is neoplasm.